Nasdaq GlobeNewswire

Ekso Bionics(R) to Establish Headquarters in Freiburg, Germany; Strengthens European Expansion Efforts

Del

RICHMOND, Calif., 2015-11-12 13:00 CET (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a leading global robotic exoskeleton company, announced today that it has established a new regional headquarters, based in Freiburg, Germany, to further strengthen its European presence and better serve German-speaking markets. The expansion is being led by Ruediger Hausherr, President, EMEA, Ekso Bionics, and marks an integral step in the company's development of its Europe, Middle East, and Africa (EMEA) business.

"Establishing this Germany-based subsidiary will allow us to enhance our customer service with training, education, and field service support by being in closer proximity to our valued customers," said Hausherr. "The Freiburg headquarters will also position Ekso to build strategic partnerships in the area."

This new site further supports Ekso Bionics' European operations by facilitating regional growth plans, establishing a dedicated sales and customer service organization to more closely liaise with leading rehabilitation centers in the region including existing customers such as Swiss Paraplegic Centre (SPC), Uppsala University Hospital, Sunnaas Hospital, BG Clinics and Schön Klinik Bad Aibling to name a few.

"We are excited to further expand our European business to meet a rise in demand for our advanced technology," said Thomas Looby, President and Chief Commercial Officer of Ekso Bionics. "I am pleased to see how Ruediger and the EMEA team have strengthened our business since he joined us in early October. Our presence in Western Europe is a strategic part of our market development and demonstrates our commitment to operational excellence."

About Ekso Bionics

Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable. Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO. www.eksobionics.com

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.

         CONTACT: Media Contact:
         Heidi Darling, Director of Marketing Communications
         Phone: 510-984-1761 x317
         E-mail: hdarling@eksobionics.com
         
         Investor Contact:
         Chad Rubin, Senior Vice President
         Phone: 646-378-2947
         E-mail: crubin@troutgroup.com

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

SoftServe Appoints Alex Chubay as Chief Technology Officer22.2.2018 13:00Pressemelding

Chubay to Champion the Next Phase of Innovation and Growth at World-Class Digital Consultancy AUSTIN, Texas, Feb. 22, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading global digital authority and consulting company, today announces its appointment of Alex Chubay as Chief Technology Officer, effective immediately. Chubay will lead global IT functions and play a key role in shaping the company's technology capabilities and roadmap. He will be responsible for SoftServe's Centers of Excellence, comprising Experience Design, Solutions, Intelligent Enterprise, Critical Services, Digital Platforms; as well as research and development within the company. He will report to SoftServe's CEO, Chris Baker. "SoftServe has operated at the cutting edge of technology for a quarter century, and to continue that momentum - and most importantly to ensure our customers, partners, and associates are served well in the future - we are delighted to announce Alex Chubay's appointment as CTO," said Baker. "This ne

Valeritas Announces V-Go® Distribution Agreement in Italy with Movi SpA22.2.2018 13:00Pressemelding

BRIDGEWATER, N.J., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with type 2 diabetes V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch and can eliminate the need for taking multiple daily shots, today announced it has signed an exclusive distribution agreement with Movi SpA ("Movi") for the commercialization of V-Go Wearable Insulin Delivery device in Italy. Under the terms of the agreement, Valeritas has granted Movi the rights to promote, market, and sell the Company's flagship product V-Go Wearable Insulin Delivery device to diabetes clinics and patients in Italy. "We are thrilled to have Movi as our partner, and our distribution agreement is a significant first step to expand market access for V-Go Wearable Insulin Delivery device outside of the United States," said John Timberlake, CEO and President of Valeritas. "Movi is a truste

Magna Announces Fourth Quarter and 2017 Results and Raises Quarterly Cash Dividend by 20%22.2.2018 11:00Pressemelding

Fourth Quarter 2017 Highlights Record sales of $10.4 billion, up 12% from the fourth quarter of 2016 Record diluted earnings per share of $1.53, an increase of 23% Cash from operations of $1.4 billion Returned $461 million to shareholders through share repurchases and dividends Raises quarterly cash dividend by 20% to $0.33 per share Full Year 2017 Highlights Record sales of $38.9 billion, up 7% from 2016 Record diluted earnings per share of $5.90, an increase of 14% Record cash from operations of $3.3 billion Returned approximately $1.3 billion to shareholders through share repurchases and $400 million in dividends. AURORA, Ontario, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX:MG) (NYSE:MGA), a technology company and one of the world's largest automotive suppliers, today reported financial results for the fourth quarter and year ended December 31, 2017. THREE MONTHS ENDED DECEMBER 31, YEAR ENDED DECEMBER 31, 2017 2016 2017 2016 Reported Sales $ 10,391 $ 9,253 $ 38,9

Fortuna Updates Reserves and Resources22.2.2018 11:00Pressemelding

VANCOUVER, British Columbia, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Fortuna Silver Mines, Inc. (NYSE:FSM) (TSX:FVI) is pleased to report updated Mineral Reserve and Mineral Resource estimates as of December 31, 2017 for the Caylloma Mine located in Peru, the San Jose Mine located in Mexico and the Lindero Project in Argentina. Jorge A. Ganoza, President and CEO, commented: "Our infill drill programs at San Jose and Caylloma mines were successful at replenishing reserves mined in 2017." Mr. Ganoza continued, "In addition, the exploration programs over the last year at Caylloma have yielded a 92 percent increase in tonnes of Inferred Resources. This success underpins the potential for this mine to continue presenting opportunities to extend its life." Highlights of Reserve and Resource Update Combined Proven and Probable Reserves for the Caylloma and San Jose mines are reported at 6.6 Mt containing 44.8 Moz silver and 273 koz gold, representing year-over-year decreases of 2 percent and 7 perc

Percona Unveils Full Conference Session Schedule for the Annual Percona Live Open Source Database Conference 201822.2.2018 09:00Pressemelding

Sponsorship Opportunities Still Available, Advance Registration Discounts End March 4, 2018 RALEIGH, N.C., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Percona, the company that delivers enterprise-class MySQL®, MariaDB and MongoDB® and other open source database solutions and services, today announced the conference session schedule for the seventh annual Percona Live Open Source Database Conference 2018, taking place April 23-25, 2018 at the Santa Clara Convention Center in Santa Clara, Calif. Sponsorship opportunities for the conference are still available. Advance Registration Discounts can be purchased through March 4, 2018, 11:30 p.m. PST. Percona Live Open Source Database Conference 2018 is the premier open source database event. With a theme of "Championing Open Source Databases," the conference will feature multiple tracks, including MySQL, MongoDB, Cloud, PostgreSQL, Containers and Automation, Monitoring and Ops, and Database Security. Once again, Percona will be offering a low-cost dat

Aurora Advanced Flow Cytometry System from Cytek Biosciences Continues to Gain Traction22.2.2018 09:00Pressemelding

Patented, Unique, Differentiated Solution Embraced by Researchers around the Globe FREMONT, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- First introduced in June of last year, the Aurora advanced flow cytometry system from Cytek Biosciences Inc. has gained significant traction in the scientific community - and is setting the new standard for what is possible. Aurora has now been sold into four continents - Asia, North America, Australia, and Europe. Cytek's mission is to fill a gap in the industry by making high-dimensional flow cytometry accessible to a larger number of researchers - and the company has its sights set on the remaining three continents. Its superb performance has enabled the possibility of new discoveries and deeper biological insights at an affordable cost. Unlike other spectral flow cytometers, Aurora is a full spectrum flow cytometer based on Cytek's innovative architecture that does not use any optical dispersive element in its fluorescence detection system. The use o

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom